These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 26203828

  • 1. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B, Li T, Guo L, Shen H, Ye S, Chen S.
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [Abstract] [Full Text] [Related]

  • 2. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 3. Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.
    Ilizaliturri-Guerra O, Uriarte-Botello R, Pineda-Sic RÁ, Serna-Peña G, Garza-Elizondo MA, Galarza-Delgado DÁ, Leal-Bramasco AS, Elizondo-Solís CV, Santoyo-Fexas L, Villarreal-Alarcón MÁ.
    Rheumatol Int; 2020 Oct; 40(10):1717-1724. PubMed ID: 32797277
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
    Serris A, Amoura Z, Canouï-Poitrine F, Terrier B, Hachulla E, Costedoat-Chalumeau N, Papo T, Lambotte O, Saadoun D, Hié M, Blanche P, Lioger B, Gottenberg JE, Godeau B, Michel M.
    Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
    [Abstract] [Full Text] [Related]

  • 5. [The efficacy and safety of low-dose rituximab in treatment of primary Sjögren's syndrome with thrombocytopenia].
    Zhou L, Xin XF, Wu HX.
    Zhonghua Nei Ke Za Zhi; 2012 Jan; 51(1):37-41. PubMed ID: 22490758
    [Abstract] [Full Text] [Related]

  • 6. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases?
    Galarza C, Valencia D, Tobón GJ, Zurita L, Mantilla RD, Pineda-Tamayo R, Rojas-Villarraga A, Rueda JC, Anaya JM.
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):124-8. PubMed ID: 18270866
    [Abstract] [Full Text] [Related]

  • 7. [Rituximab therapy for severe pediatric systemic lupus erythematosus].
    Su GX, Wu FQ, Wang F, Zhou ZX, Huang XL, Lu J.
    Zhonghua Er Ke Za Zhi; 2012 Sep; 50(9):697-704. PubMed ID: 23158822
    [Abstract] [Full Text] [Related]

  • 8. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus.
    Olfat M, Silverman ED, Levy DM.
    Lupus; 2015 Aug; 24(9):966-72. PubMed ID: 25804672
    [Abstract] [Full Text] [Related]

  • 9. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
    Ramos-Casals M, García-Hernández FJ, de Ramón E, Callejas JL, Martínez-Berriotxoa A, Pallarés L, Caminal-Montero L, Selva-O'Callaghan A, Oristrell J, Hidalgo C, Pérez-Alvarez R, Micó ML, Medrano F, Gómez de la Torre R, Díaz-Lagares C, Camps M, Ortego N, Sánchez-Román J, BIOGEAS Study Group.
    Clin Exp Rheumatol; 2010 Aug; 28(4):468-76. PubMed ID: 20525449
    [Abstract] [Full Text] [Related]

  • 10. Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.
    Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S.
    Arthritis Rheumatol; 2019 Nov; 71(11):1812-1823. PubMed ID: 31131994
    [Abstract] [Full Text] [Related]

  • 11. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.
    Seror R, Sordet C, Guillevin L, Hachulla E, Masson C, Ittah M, Candon S, Le Guern V, Aouba A, Sibilia J, Gottenberg JE, Mariette X.
    Ann Rheum Dis; 2007 Mar; 66(3):351-7. PubMed ID: 16950808
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece.
    Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F.
    Rheumatol Int; 2013 Mar; 33(3):809-13. PubMed ID: 22101555
    [Abstract] [Full Text] [Related]

  • 13. Effectiveness and Safety of Rituximab in Systemic Lupus Erythematosus: A Case Series Describing the Experience of 2 Centers.
    Gómez VJ, Carrión-Barberá I, Salman Monte TC, Acosta A, Torrente-Segarra V, Monfort J.
    Reumatol Clin (Engl Ed); 2020 Mar; 16(5 Pt 2):391-395. PubMed ID: 30522941
    [Abstract] [Full Text] [Related]

  • 14. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry.
    Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, Bonnet C, Cacoub P, Cantagrel A, de Bandt M, Fain O, Fautrel B, Gaudin P, Godeau B, Harlé JR, Hot A, Kahn JE, Lambotte O, Larroche C, Léone J, Meyer O, Pallot-Prades B, Pertuiset E, Quartier P, Schaerverbeke T, Sibilia J, Somogyi A, Soubrier M, Vignon E, Bader-Meunier B, Mariette X, Gottenberg JE, Club Rhumatismes et Inflammation.
    Arthritis Rheum; 2010 Aug; 62(8):2458-66. PubMed ID: 20506527
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY Trials.
    Gottenberg JE, Dörner T, Bootsma H, Devauchelle-Pensec V, Bowman SJ, Mariette X, Bartz H, Oortgiesen M, Shock A, Koetse W, Galateanu C, Bongardt S, Wegener WA, Goldenberg DM, Meno-Tetang G, Kosutic G, Gordon C.
    Arthritis Rheumatol; 2018 May; 70(5):763-773. PubMed ID: 29381843
    [Abstract] [Full Text] [Related]

  • 16. Severe thrombocytopenia in connective tissue diseases: a single-center review of 131 cases.
    Zhang W, Wang F, Wang H, Hua B, Feng X, Sun L.
    Clin Rheumatol; 2018 Dec; 37(12):3337-3344. PubMed ID: 30276563
    [Abstract] [Full Text] [Related]

  • 17. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience Over 14 Years.
    Aguiar R, Araújo C, Martins-Coelho G, Isenberg D.
    Arthritis Care Res (Hoboken); 2017 Feb; 69(2):257-262. PubMed ID: 27110698
    [Abstract] [Full Text] [Related]

  • 18. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases.
    Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, Larroche C, Soubrier M, Bouillet L, Dougados M, Fain O, Farge D, Kyndt X, Lortholary O, Masson C, Moura B, Remy P, Thomas T, Wendling D, Anaya JM, Sibilia J, Mariette X, Club Rheumatismes et Inflammation (CRI).
    Ann Rheum Dis; 2005 Jun; 64(6):913-20. PubMed ID: 15550531
    [Abstract] [Full Text] [Related]

  • 19. Evidence for the Detection of Subclinical Retinal Involvement in Systemic Lupus Erythematosus and Sjögren Syndrome: A Potential Association with Therapies.
    Conigliaro P, Triggianese P, Draghessi G, Canofari C, Aloe G, Chimenti MS, Valeri C, Nucci C, Perricone R, Cesareo M.
    Int Arch Allergy Immunol; 2018 Jun; 177(1):45-56. PubMed ID: 29902805
    [Abstract] [Full Text] [Related]

  • 20. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study.
    You C, Lamba N, Lasave AF, Ma L, Diaz MH, Foster CS.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1221-1228. PubMed ID: 28154932
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.